Science (Faculty of)

Permanent URI for this communityhttps://uwspace.uwaterloo.ca/handle/10012/9936

Welcome to the Faculty of Science community.

This community and its collections are organized using the University of Waterloo's Faculties and Academics structure. In this structure:

  • Communities are Faculties or Affiliated Institutions
  • Collections are Departments or Research Centres

Research outputs are organized by type (eg. Master Thesis, Article, Conference Paper).

Browse

Browsing Science (Faculty of) by Author "Alsabbagh, Mhd. Wasem"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitor use
    (University of Waterloo, 2021-05-19) Huang, Yichang; Alsabbagh, Mhd. Wasem
    Background: Acquired long-QT syndrome (ALQTS) and its associated condition, torsades de pointes (TdP – a malignant cardiac arrhythmia), are associated with the use of certain medications. Case reports and pharmacodynamic studies suggest donepezil, one of the three acetylcholinesterase inhibitors (AChEIs) used in the treatment of Alzheimer’s Disease (AD) and related dementias, may be associated with a greater risk of ALQTS and malignant arrhythmias. Only a limited number of studies have generated relevant information, and no population-based epidemiologic studies have directly examined comparative risk between AChEIs. Methods: Using Canadian hospitalization and prescription medication administrative databases – the Discharge Abstract Database (DAD) and National Prescription Drug Utilization Information System (NPDUIS) respectively – I included individuals in seven jurisdictions (British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Prince Edward Island, Newfoundland and Labrador) between April 1st 2011 and January 31st 2019. Included adults were aged 66 and over, and either initiated the use of donepezil, galantamine, oral rivastigmine, or transdermal rivastigmine (defined as no previous dispensation of AChEI recorded in NPDUIS in 365 days prior). The outcome of a hospitalization for malignant arrhythmia was identified by ICD-10-CA codes I47.2 and I49.00. The hospitalization date set as the 15th of the month in primary analysis (with adjustment to first or end of month in sensitivity analyses) and a multivariable Cox regression model was fitted to estimate the hazard of a hospitalization for malignant arrhythmia, dependent upon AChEI use. The primary analysis assessed the time to hospitalization for malignant arrhythmia using the primary DAD diagnostic field and a maximum available follow-up of eight years. In secondary analyses, I included malignant arrhythmia codes from any diagnostic field and limited follow-up to 365 days. Variables adjusted for include demographic covariates and comorbidities identified from previous hospitalizations and prescription medication use. Results: The cohort included 162,527 patients (mean age 82, 40% male; median days follow-up 386). Most subjects (n = 127,038; 78%) were treated with donepezil, while 25,582 (16%) received galantamine and 9,907 (6%) received rivastigmine. During a median follow up of 1.06 years, I identified 90 hospitalizations for a malignant arrhythmia – including 58 in the donepezil group (23 per 100,000 person-years) and 32 for other AChEIs (44 per 100,000 person-years). After adjustment for confounding, initiation of donepezil was associated with a 45% lower hazard of hospitalization (adjusted HR 0.55, 95% CI 0.36 to 0.85) relative to other AChEIs as a group. When assessing for malignant arrhythmias occurring in any diagnosis field, I identified 336 events (258 in the donepezil group and 78 in other AChEIs group); however, donepezil initiation was no longer significantly associated with hospitalizations (adjusted HR 1.01, 95% CI 0.78 to 1.30). My findings were similar in an analysis limited to 365 days of follow-up, and in sensitivity analyses modifying the hospitalization date definition (since only month/year of hospitalization was provided). Conclusion: In this large, population-based cohort study, initiation of donepezil was not associated with an increased risk of hospitalization for malignant arrhythmias in comparison to other AChEIs. This was not consistent with case reports and pharmacodynamic studies. Given that adjustment for confounders moved the HR towards the null, residual confounding, caused by uncaptured comorbidities may have caused the lower risk in the donepezil group (e.g., since donepezil is a first line AChEI for treatment of Alzheimer’s). Further research is warranted.
  • Thumbnail Image
    Item
    The impact of prescription medication cost coverage on optimal adherence to Hypertension and Diabetes Mellitus oral medications
    (University of Waterloo, 2018-02-26) Amoud, Razan; Alsabbagh, Mhd. Wasem
    Background: It can be difficult for patients who do not have prescription medication cost coverage to adhere to their medications. No previous study has examined the time-trend and impact of absence of coverage on adherence to oral diabetes and hypertension medications in Canada. Methods: Using data from the Canadian Community Health Survey cycles 2007, 2008, 2013, and 2014, I included individuals from participating provinces that opted to include questions about coverage (Ontario and New Brunswick). Included adults had either hypertension or diabetes and answered questions on both coverage and adherence to medications. A multivariate-adjusted logistic regression model was fitted to estimate the odds of non-adherence depending on coverage. I adjusted for confounding variables including demographic factors (socioeconomic status; age, education, sex, province of residence), and health system and behaviour variables (such as smoking, having a regular doctor, not receiving a flu shot, as well as having additional comorbidities). Results: The pseudo-cohort included 23,215 individuals. The weighted average age was 60 years. 20% of participants reported absence of coverage. This percentage increased slightly over the study period. Patients with no prescription medication coverage were at 23% higher odds of not adhering to their medication (adjusted odds ratio (OR) 0.77; 95% CI (Confidence Interval) 0.657 - 0.911). Subgroup analysis revealed that patients aged less than 65 years, lived in Ontario, and had a middle-income were also at a statistically significant lower odd for adherence with absence of insurance. Conclusion: Absence of prescription medication coverage is associated with a reduced adherence to diabetes and hypertension oral medications. Providing medication coverage may help in increasing the probability for adherence. As such, there is a need for further studies to quantify the effect of recent changes of provincial insurance coverage.
  • Thumbnail Image
    Item
    Pharmacy patron perspectives of community pharmacist administered influenza vaccinations
    (Elsevier, 2019-02) Alsabbagh, Mhd. Wasem; Church, Dana; Wenger, Lisa; Papastergiou, John; Raman-Wilms, Lalitha; Schneider, Eric; Waite, Nancy
    One approach to boost influenza vaccination coverage has been to expand immunization authority. In 2012, the province of Ontario gave community pharmacists the authority to administer the influenza vaccine.